CN116200305A - 一株具有抗炎特性的耐久肠球菌菌株、培养方法及应用 - Google Patents
一株具有抗炎特性的耐久肠球菌菌株、培养方法及应用 Download PDFInfo
- Publication number
- CN116200305A CN116200305A CN202310060366.7A CN202310060366A CN116200305A CN 116200305 A CN116200305 A CN 116200305A CN 202310060366 A CN202310060366 A CN 202310060366A CN 116200305 A CN116200305 A CN 116200305A
- Authority
- CN
- China
- Prior art keywords
- inflammatory
- enterococcus
- enterococcus durans
- product
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000520130 Enterococcus durans Species 0.000 title claims abstract description 70
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 55
- 238000012136 culture method Methods 0.000 title abstract description 5
- 230000014509 gene expression Effects 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 19
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 16
- 230000000770 proinflammatory effect Effects 0.000 claims abstract description 11
- 102000004162 Claudin-1 Human genes 0.000 claims abstract description 10
- 108090000600 Claudin-1 Proteins 0.000 claims abstract description 10
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract description 10
- 102000003940 Occludin Human genes 0.000 claims abstract description 10
- 108090000304 Occludin Proteins 0.000 claims abstract description 10
- 230000036541 health Effects 0.000 claims abstract description 4
- 239000003674 animal food additive Substances 0.000 claims abstract description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims abstract description 3
- 241000194033 Enterococcus Species 0.000 claims description 21
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 108050009302 Claudin Proteins 0.000 claims description 4
- 102000003814 Interleukin-10 Human genes 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 102000002029 Claudin Human genes 0.000 claims 1
- 229940122498 Gene expression inhibitor Drugs 0.000 claims 1
- 239000006872 mrs medium Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 abstract description 18
- 230000000968 intestinal effect Effects 0.000 abstract description 18
- 206010061218 Inflammation Diseases 0.000 abstract description 16
- 230000004054 inflammatory process Effects 0.000 abstract description 16
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 abstract description 12
- 241000588724 Escherichia coli Species 0.000 abstract description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 9
- 244000005700 microbiome Species 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 238000004321 preservation Methods 0.000 abstract description 4
- 241001573498 Compacta Species 0.000 abstract description 2
- 210000004082 barrier epithelial cell Anatomy 0.000 abstract 1
- 230000004890 epithelial barrier function Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 34
- 239000013642 negative control Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 13
- 229920003045 dextran sodium sulfate Polymers 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 206010012735 Diarrhoea Diseases 0.000 description 11
- 241000194031 Enterococcus faecium Species 0.000 description 10
- 239000002504 physiological saline solution Substances 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 235000019687 Lamb Nutrition 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000006041 probiotic Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000283903 Ovis aries Species 0.000 description 6
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 210000002175 goblet cell Anatomy 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010002321 Tight Junction Proteins Proteins 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- -1 ZO-1 Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 2
- 229940025294 hemin Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004682 mucosal barrier function Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 2
- 235000019175 phylloquinone Nutrition 0.000 description 2
- 239000011772 phylloquinone Substances 0.000 description 2
- 229960001898 phytomenadione Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 240000001606 Adenanthera pavonina Species 0.000 description 1
- 235000011470 Adenanthera pavonina Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001605679 Colotis Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241001502625 Endococcus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 241000871744 Lactobacillus casei LC2W Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 230000037037 animal physiology Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明属于微生物技术领域,具体涉及一株具有抗炎特性的耐久肠球菌(Enterococcus durans)98D、培养方法及应用。所述耐久肠球菌的保藏编号为CCTCC NO:M 20221217,其能够恢复DSS及大肠杆菌诱导的肠道炎症、提高结肠上皮屏障完整性、降低促炎基因TNF‑α、IL‑6、IL‑1β表达水平、提高抑炎基因IL‑10及紧密连接蛋白基因ZO‑1、Occludin、Claudin‑1的表达水平,具有对肠道炎症的治疗作用,能够抗炎药物、抗炎保健品或者抗炎饲料添加剂等抗炎产品。
Description
技术领域
本发明属于微生物技术领域,具体涉及一株具有抗炎特性的耐久肠球菌(Enterococcus durans)98D、培养方法及应用。
背景技术
炎症性肠病是一种病因不明的慢性非特异性肠道炎性疾病,包括克罗恩病和溃疡性结肠炎,已成为21世纪全球发病率加速上升的全球性疾病。遗传因素、粘膜屏障功能缺陷、先天免疫和获得性免疫以及微生物组成的改变都可能导致炎症性肠病的发生和发展。炎症性肠病患者临床症状包含持续腹痛、体重减轻、食欲下降和精神萎靡等。炎症性肠病传统的治疗方法可分为现代医学治疗和中药治疗法,这些方法或具有一定副作用或见效缓慢。随着科学技术的发展,肠道微生物与炎症性肠病相关性研究为该病的治疗提供了新的治疗手段,即通过体外补充益生菌以调节肠道菌群平衡从而治疗炎症性肠病。
益生菌是一种活的微生物,当给予足够的量时,会对宿主产生有益的影响。它们通过调节肠道微生物区系,促进粘膜屏障功能和对病原体的抵抗力来发挥这些作用。目前,临床上认为益生菌能够维持或缓解炎症性肠病的临床发展。益生菌的作用机制主要通过4种方式实现:抑制病原菌或与其竞争、增强肠道上皮的屏障功能、调节宿主免疫功能、参与肠-脑轴调节。
耐久肠球菌属乳酸菌属,能够适应复杂的环境,广泛存在于从昆虫到人类的各个物种的胃肠道中。一些肠球菌菌株具有改善人类健康的功能。然而,其他研究也表明某些肠球菌菌株也与感染的发生有关,例如一些粪肠球菌和屎肠球菌菌株分泌的黏附素、侵袭素及溶血素等会引起人类感染。在动物中,肠球菌的益生作用主要体现在对肠道炎症的预防或治疗作用。Zeyner和Boldt的研究显示,将屎肠球菌作为添加剂可以成功降低腹泻仔猪的比例、提高仔猪的生长发育并减少肠道中致病菌的定殖(A.Zeyner,E.Boldt,Effects of aprobiotic Enterococcus faecium strain supplemented from birth to weaning ondiarrhoea patterns and performance of piglets.Journal of animal physiologyand animal nutrition 90,25-31(2006))。此外,Enterococcus.faecium(NCIMB10415)已被批准用于动物饲料的添加剂,该菌不仅可以降低动物肠道内致病菌的负荷和大肠杆菌毒力基因的表达,还可以引发抗炎反应。石陆娥等(石陆娥,唐振兴,郑伟,张瑜.屎肠球菌KQ2.6及应用[P].浙江省:CN104560820B,2017-10-20)从新鲜孔雀粪便中分析筛选出一株屎肠球菌(Enterococcus.faecium KQ2.6),用于抑制常见病原微生物的繁殖。马曦等(马曦,姬琳堡,孙美鸽,张中岳,罗小华,王贤锋,陈柱生.一株屎肠球菌及其应用[P].江苏省:CN112063566B,2021-11-02)从肉牛瘤胃中筛选并经过紫外诱变得到一株屎肠球菌(Enterococcus.faecium AH01),能够有效粘附于动物肠道并对革兰氏阳性、阴性菌均有抑制作用。基于以上所述,益生菌对于肠道疾病的治疗具有很好的前景,但是,其他肠球菌是否具有治疗肠道炎症的潜力及作用机制都有待探究。因此,本发明的目的是提供一株具有优异益生特性,能够有效治疗肠道炎症的耐久肠球菌菌株。/>
发明内容
为了解决上述技术问题,本发明提供了一株具有抗炎特性的耐久肠球菌菌株、培养方法及应用。
本发明的目的是提供一种具有抗炎特性的耐久肠球菌菌株,命名为98D,该菌株已于2022年8月03日保藏于中国典型培养物保藏中心,保藏编号为CCTCC NO:M 20221217。
本发明还提供了一种上述具有抗炎特性的耐久肠球菌菌株的培养方法,将单个菌落接种于MRS培养基中,37℃好氧培养24h,得到耐久肠球菌菌液。
本发明还提供了一种包含上述具有抗炎特性的耐久肠球菌菌株的抗炎产品。
优选的,所述抗炎产品为抗炎药物、抗炎保健品或者抗炎饲料添加剂。
优选的,所述抗炎产品为片剂、散剂、粉剂、颗粒剂、胶囊剂、液体制剂中的任意一种。
优选的,所述抗炎产品是将所述耐久肠球菌以活菌或死菌的固态或液态菌制剂的形式制备成的。
优选的,如果是液态抗炎产品,则所述抗炎产品中耐久肠球菌含量≥109cfu/mL;如果是固态抗炎产品,则所述抗炎产品中耐久肠球菌含量≥109cfu/g。
本发明还提供了一种所述的具有抗炎特性的耐久肠球菌菌株的应用,所述耐久肠球菌菌株用于制备治疗溃疡性结肠炎症的产品。
优选的,所述耐久肠球菌菌株用于制备促炎基因表达抑制剂,或者用于制备抑炎基因及紧密连接蛋白基因表达促进剂,或者用于制备血清中IFN-γ与LPS的浓度调节剂。
优选的,所述促炎基因为TNF-α、IL-6和IL-1β,所述抑炎基因为IL-10,所述紧密连接蛋白基因为ZO-1、Occludin和Claudin-1。
与现有技术相比,本发明具有以下有益效果:
本发明所述耐久肠球菌98D可使用于动物或是人类。所述耐久肠球菌还可配合所属领域中的常规用料组分;例如,对于药物组合物,可包括适量的辅料,所述辅料可以为赋型剂、稀释剂、填充剂、吸收促进剂等;对于食品组合物,本发明的耐久肠球菌可以按照现有技术中含耐久肠球菌的食品进行生产,所述组合物可根据受施予者的需要,而采用不同形态。例如粉剂、锭剂、造粒、微胶囊、液体制剂等。
本发明发掘了耐久肠球菌新的用途,开拓了一个新的应用领域。本发明通过实验证明,耐久肠球菌安全无毒,药理作用强,对于肠道炎症有很好的治疗作用,从而预示了耐久肠球菌具有很好的食用和药用前景。耐久肠球菌作为一种益生菌,可用于制备治疗炎症性肠病的食品或药物组合物,进而为临床提供适合人体服用的保健食品或治疗药物。
根据本发明的具体实施方案,所述组合物是用于下调促炎基因IL-6和/或TNF-α和/或IL-1β的表达,上调抑炎基因IL-10及紧密连接蛋白基因ZO-1、Occludin和Claudin-1的表达。具体应用时,所述耐久肠球菌的应用量应达到5×109CFU/mL,以起到缓解和治疗肠道炎症的作用。
生物保藏信息说明
一种耐久肠球菌(Enterococcus durans),命名为Enterococcus durans 98D,简称为98D。该菌株已于2022年8月3日保藏于中国典型培养物保藏中心CCTCC(地址:湖北省武汉市武昌区八一路珞珈山,武汉大学),分类命名:耐久肠球菌(Enterococcus durans);保藏编号为CCTCC NO:M 20221217。
附图说明
图1是耐久肠球菌98D的平板培养图;
图2是本发明实施例2中耐久肠球菌对DSS诱导的肠道炎症小鼠体重的影响;
图3是本发明实施例2中耐久肠球菌对DSS诱导的肠道炎症小鼠结肠长度的影响;A为长度测量统计图,B为结肠实物长度测量;
图4是本发明实施例2中耐久肠球菌对DSS诱导的肠道炎症小鼠结肠杯状细胞数的影响;A为小鼠结肠上皮中杯状细胞数量统计结果,B为小鼠结肠上皮中杯状细胞染色结果;
图5是本发明实施例2中耐久肠球菌对DSS诱导的肠道炎症小鼠结肠组织基因表达量的影响;A-G分别为TNF-α、IL-6、IL-1β、IL-10、ZO-1、Occludin、Claudin-1;
图6是实施例3中耐久肠球菌对大肠杆菌诱导的肠道炎症小鼠结肠组织基因表达量的影响;A-G分别为IL-6、IL-1β、TNF-α、IL-10、Occludin、Claudin-1、ZO-1;
图7是实施例4耐久肠球菌98D在治疗大肠杆菌诱导的羔羊腹泻方面相关因子浓度的影响;A-F分别为DAI Score、IFN-γ、IL-1β、TNF-α、IL-6、LPS。
具体实施方式
为了使本领域技术人员更好地理解本发明的技术方案能予以实施,下面结合具体实施例和附图对本发明作进一步说明。
在本发明的描述中,如未特殊说明,所用试剂均为市售,所用方法均为本领域常规技术。
实施例1耐久肠球菌98D菌液的制备
(1)由羔羊粪便中分离耐久肠球菌98D
收集新鲜的羔羊粪便1g悬浮于PBS缓冲液中,6000r/min离心5min并收集上清液,连续稀释至10-8倍。9g布氏培养基粉末中加入3g琼脂,加无菌水定容至196mL,高压蒸汽灭菌后,加入0.01‰氯化血红素(即氯化血红素终浓度0.01‰,w/v)、0.01‰维生素K1(即维生素K1终浓度0.01‰,w/v)、0.1‰卡那霉素(即卡那霉素终浓度0.1‰,w/v)、0.0075‰万古霉素(即万古霉素终浓度0.0075‰,w/v)以及5%脱纤维绵羊血(即脱纤维绵羊血终浓度5%,w/v)配置成固体改良布氏血(LKV)培养基。将50μL粪便上清液涂板至固体改LKV培养基上,37℃好氧培养24h后挑取单菌落进行菌种鉴定并纯化培养,得到目标菌株。
耐久肠球菌98D平板培养结果参见图1。
(2)耐久肠球菌98D全基因组测序;
采用农业农村部印发的《直接饲喂微生物和发酵制品生产菌株鉴定及其安全性评价指南》方法,对耐久肠球菌98D基因组中抗生素耐药基因按照覆盖度≥70%,匹配度≥80%进行筛选。评价结果显示,耐久肠球菌98D对氟喹诺酮类、大环内酯类、利福霉素类以及氨基糖苷类抗生素敏感。后经体外药敏实验进一步验证后显示,上述抗生素均可抑制耐久肠球菌98D的生长。因此,耐久肠球菌98D符合欧洲食品安全委员会(European Food SafetyAuthority)对食用细菌耐药性评价规范中的要求。耐久肠球菌98D不含外源抗生素耐药基因,食用安全。
耐久肠球菌16s rRNA基因序列测序结果如下:
CTAATTCTGTCACTTCGGCGGCTGGCTCCTAAAGGTTACCTCACCGACTTCGGGTGTTACAAACTCTCGTGGTGTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCGGCATGCTGATCCGCGATTACTAGCGATTCCAGCTTCACGCAGTCGAGTTGCAGACTGCGATCCGAACTGAGAACAGATTTGTGGGATTGGCTTAACCTCGCGGTTTCGCTGCCCTTTGTTCTGTCCATTGTAGCACGTGTGTAGCCCAGGTCATAAGGGGCATGATGATTTGACGTCATCCCCACCTTCCTCCGGTTTGTCACCGGCAGTCACCTTAGAGTGCCCAACTGAATGCTGGCAACTAAGATCAAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAACCATGCACCACCTGTCACTCTGCCCCCGAAGGGGACGTCCTATCTCTAGGATTGTCAGAGGATGTCAAGACCTGGTAAGGTTCTTCGCGTTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTCAGTCTTGCGACCGTACTCCCCCAGGCGGAGTGCTTAATGCGTTAGCTGCAGCACTAAGGGGCGGAAACCCCCTAACACTTAGCACTCATCGTTTACGGCGTGGACTACCAGGGTATCTAATCCTGTTCGCTCCCCACGCTTTCGCTCCTCAGCGTCAGTTACAGACCAGAGAGTCGCCTTCGCCACTGGTGTTCCTCCACATCTCTACGCATTTCACCGCTACACGTGGAATTCCACTCTCCTCTTCTGCACTCAAGTTCCCCAGTTTCCAATGACCCTCCCCGGTTGAGCCGGGGGCTTTCACATCAGACTTAAGAAACCGCCTGCGAGCCCTTTACGCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGTAGTTAGCCGTGGCTTTCTGGTTAGGTACCGTCAAGGTACCGCCCTATTCGAACGGTACTTGTTCTTCCCTAACAACAGAGCTTTACGATCCGAAAACCTTCATCACTCACGCGGCGTTGCTCCGTCAGACTTTCGTCCATTGCGGAAGATTCCCTACTGCTGCCTCCCGTAGGAGTCTGGGCCGTGTCTCAGTCCCAGTGTGGCCGATCACCCTCTCAGGTCGGCTACGCATCGTTGCCTTGGTGAGCCGTTACCTCACCAACTAGCTAATGCGCCGCGGGTCCATCTGTAAGTGGTAGCCGAAGCCACCTTTTATGTTTGAACCATGCGGTTCAAACAACCATCCGGTATTAGCCCCGGTTTCCCGGAGTTATCCCAGTCTTACAGGCAGGTTACCCACGTGTTACTCACCCGTCCGCCGCTAACATCAGGGAGCAAGCTCCCATCTGTCCGCTCGACTGCATGTATAGCACGCGGACATGCAC
(3)耐久肠球菌98D的富集培养及菌液制备
选取纯化好的单个菌落接种于MRS培养基中进行富集培养(37℃好氧培养24h),并取培养后的菌液在5000r/min、4℃条件下离心10min,弃去上清,并用生理盐水洗涤、重悬后进行梯度稀释,以调整耐久肠球菌98D的浓度,保存备用。
实施例2耐久肠球菌98D对于炎症性肠病的短期治疗作用
采用实施例1(3)制备的耐久肠球菌98D菌液进行以下实验:
实验动物:C57BL/6J雌性小鼠。
动物模型构建:化学药物诱导炎症性肠病(葡聚糖硫酸钠DSS诱导溃疡性结肠炎)。
动物试验设计:取24只小鼠随机分为3组:阴性对照组(NC)、阳性对照组(Con)、耐久肠球菌处理组(En.d)。试验第0-14d,NC小鼠自由饮水,Con和En.d组小鼠自由饮用含有3% DSS的饮用水。试验15-24d,NC小鼠自由饮水,Con和En.d组小鼠仍自由饮用含3g/100mLDSS的饮用水,此外,NC和Con组小鼠每日灌胃200μL生理盐水,En.d组小鼠每日灌胃200μL含5×109CFU/mL Enterococcus durans 98D的生理盐水,于第24d处死小鼠并采样。
测量指标:小鼠体重、小鼠结肠长度、结肠组织切片AB-PAS染色、结肠组织杯状细胞数、促炎基因(TNF-α、IL-6、IL-1β)、抑炎基因IL-10及紧密连接蛋白基因(ZO-1、Occludin、Claudin-1)表达量。
试验结果:如图2所示,与NC组相比,DSS处理后Con组小鼠的体重显著下降,En.d组小鼠体重显著上升(P<0.05),结果显示,耐久肠球菌98D能够防止DSS导致的小鼠体重降低。如图3所示,NC组结肠长度最长,其次为En.d组,最后为Con组,结果显示,耐久肠球菌98D处理能够显著缓解DSS影响下的结肠长度变短(P<0.05)。如图4所示,与Con组相比,En.d组小鼠结肠上皮中杯状细胞数量显著上升(P<0.05),说明耐久肠球菌98D处理能够显著改善DSS处理下小鼠的肠道上皮屏障完整性。如图5所示,与Con组相比,En.d组小鼠结肠组织中促炎基因TNF-α、IL-6、IL-1β的表达水平显著降低(P<0.05),且抑炎基因IL-10的表达水平显著升高(P<0.05)。此外,En.d组小鼠结肠上皮组织中紧密连接蛋白基因ZO-1、Occludin、Claudin-1的表达量显著高于Con组小鼠(P<0.05)。
实施例2的实验结果说明耐久肠球菌98D炎症性肠病尤其是溃疡性结肠炎有治疗作用。
实施例3耐久肠球菌98D抑制肠道致病菌的作用
采用实施例1(3)制备的耐久肠球菌98D菌液进行以下实验:
(1)抑菌实验
致病菌种类:金黄色葡萄球菌、大肠杆菌、枯草芽孢杆菌、幽门螺杆菌、沙门氏菌。
实验方法:牛津杯法,将孵育18h的致病菌菌液0.2ml、菌体浓度107CFU/mL分别均匀涂布接种于营养琼脂平板上,平板中心放置牛津杯,每个牛津杯中装有0.2ml实施例1(3)制备的耐久肠球菌98D菌液;用无菌水0.2ml作为阴性对照。上述体系在37℃培养24h,测量抑菌圈直径,测量3次,求取平均值。
实验结果:结果参见表1。
表1耐久肠球菌抑菌实验结果
(2)动物实验
实验动物:6周龄C57BL/6J雌性小鼠。
动物模型构建:大肠杆菌O157:H7诱导肠道炎症的模型参考(Wang,G.,Tang,H.,Zhang,Y.,Xiao,X.,Xia,Y.,&Ai,L.(2020).The intervention effects ofLactobacillus casei LC2W on Escherichia coli O157:H7-induced mousecolitis.Food Science and Human Wellness,9(3),289-294.)。
动物试验设计:取24只小鼠随机分为3组:阴性对照组(NC)、阳性对照组(Con)、耐久肠球菌处理组(En.d)。试验第0-3d,所有实验小鼠饮用含有5g/L链霉素的饮水,以抑制肠道中微生物,为植入大肠杆菌O157:H7做准备。第4-13d,NC小鼠每天灌胃生理盐水0.6mL;Con组小鼠每日灌胃0.3mL大肠杆菌O157活菌浓度含量为1×109CFU/mL的生理盐水,同时灌胃0.3mL的生理盐水;En.d组小鼠灌胃0.3mL大肠杆菌O157活菌浓度为2×109CFU/mL的生理盐水,同时灌胃耐久肠球菌98D活菌含量为2×109CFU/mL的生理盐水0.3mL;于第14天处死小鼠并采样。
测量指标:促炎基因(TNF-α、IL-6、IL-1β)、抑炎基因IL-10、ZO-1、Occludin、Claudin-1的表达量。
试验结果:如图6所示,与Con组相比,En.d组小鼠结肠组织中促炎基因TNF-α、IL-6、IL-1β的表达水平显著降低(P<0.05),且抑炎基因IL-10的表达水平显著升高(P<0.05)。此外,En.d组小鼠结肠上皮组织中紧密连接蛋白基因ZO-1、Occludin、Claudin-1的表达量显著高于Con组小鼠(P<0.05)。
实施例3的实验结果说明耐久肠球菌98D炎症性肠病尤其是溃疡性结肠炎有治疗作用。
实施例4耐久肠球菌98D在治疗大肠杆菌诱导的羔羊腹泻方面的效果实验
实验分组:取18只60d羔羊随机分为3组,阴性对照组(NC)、阳性对照组(Con)、耐久肠球菌处理组(En.d),试验共分为两阶段。试验第一阶段:阴性对照组(NC)处理对象为健康羔羊,每日晨饲前灌胃5mL生理盐水;阳性对照组(Con)及耐久肠球菌处理组(En.d)羔羊每日晨饲前灌胃5mL含1×1012CFU/mL肠出血性大肠杆菌O157的生理盐水,试验第一阶段持续7d。试验第二阶段:NC组和Con组羔羊于每日晨饲前灌胃5mL生理盐水;En.d组羔羊每日晨饲前灌胃5mL含1×1012CFU/mL Enterococcus durans 98D的生理盐水,试验第二阶段持续14d。
测量指标:羔羊腹泻评分、血清炎症因子(TNF-α、IL-6、IL-1β、IFN-γ、LPS)的浓度。
羔羊腹泻评分标准:腹泻指数评分标准:以滩羊粪便形态、***周围皮肤洁净程度及炎症情况为评价指标,按照表2分为0、1、2、3等级将羔羊腹泻进行量化。
表2羔羊腹泻指数评分标准
试验结果:如图7所示,与Con组相比,En.d组小鼠DAI Score最终降低趋势;与Con组相比,En.d组小鼠结肠组织中IFN-γ、IL-1β、TNF-α、IL-6、LPS的浓度显著降低(P<0.05),)。
已有研究结果显示TNF-α、IL-6、IL-1β、IFN-γ及LPS等与糖尿病、肠道炎症、静脉血栓等疾病相关。结合实施例2、实施例3及实施例4,本发明首次发现,耐久肠球菌98D不但能够影响组织中TNF-α、IL-6、IL-1β等促炎因子基因的表达量,也能够调控血清中TNF-α、IL-6、IL-1β及LPS的浓度。同时,化学腹泻及生物腹泻模型的共同验证也表明耐久肠球菌在治疗肠道炎症方面具有广泛的应用前景。
需要说明的是,本发明中涉及数值范围时,应理解为每个数值范围的两个端点以及两个端点之间任何一个数值均可选用,由于采用的步骤方法与实施例相同,为了防止赘述,本发明描述了优选的实施例。尽管已描述了本发明的优选实施例,但本领域内的技术人员一旦得知了基本创造性概念,则可对这些实施例做出另外的变更和修改。所以,所附权利要求意欲解释为包括优选实施例以及落入本发明范围的所有变更和修改。
显然,本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样,倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内,则本发明也意图包含这些改动和变型在内。
Claims (10)
1.一株具有抗炎特性的耐久肠球菌(Enterococcus durans)菌株,其特征在于,命名为98D,该菌株已于2022年8月3日保藏于中国典型培养物保藏中心,保藏编号为CCTCC NO:M20221217。
2.根据权利要求1所述的具有抗炎特性的耐久肠球菌菌株的培养方法,其特征在于,将单个菌落接种于MRS培养基中,37℃好氧培养24h,得到耐久肠球菌菌液。
3.一种包含权利要求2所述的具有抗炎特性的耐久肠球菌菌株的抗炎产品。
4.根据权利要求3所述的具有抗炎特性的耐久肠球菌菌株的抗炎产品,其特征在于,所述抗炎产品为抗炎药物、抗炎保健品或者抗炎饲料添加剂。
5.根据权利要求3所述的具有抗炎特性的耐久肠球菌菌株的抗炎产品,其特征在于,所述抗炎产品为片剂、散剂、粉剂、颗粒剂、胶囊剂、液体制剂中的任意一种。
6.根据权利要求3所述的具有抗炎特性的耐久肠球菌菌株的抗炎产品,其特征在于,所述抗炎产品是将所述耐久肠球菌以活菌或死菌的固态或液态菌制剂的形式制备成的。
7.根据权利要求3所述的具有抗炎特性的耐久肠球菌菌株的抗炎产品,其特征在于,如果是液态抗炎产品,则所述抗炎产品中耐久肠球菌含量≥109cfu/mL;如果是固态抗炎产品,则所述抗炎产品中耐久肠球菌含量≥109cfu/g。
8.根据权利要求1所述的具有抗炎特性的耐久肠球菌菌株的应用,其特征在于,所述耐久肠球菌菌株用于制备治疗溃疡性结肠炎症的产品。
9.根据权利要求8所述的具有抗炎特性的耐久肠球菌菌株的应用,其特征在于,所述耐久肠球菌菌株用于制备促炎基因表达抑制剂,或者用于制备抑炎基因及紧密连接蛋白基因表达促进剂,或者用于制备血清中IFN-γ与LPS的浓度调节剂。
10.根据权利要求9所述的具有抗炎特性的耐久肠球菌菌株的应用,其特征在于,所述促炎基因为TNF-α、IL-6和IL-1β,所述抑炎基因为IL-10,所述紧密连接蛋白基因为ZO-1、Occludin和Claudin-1。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310060366.7A CN116200305A (zh) | 2023-01-14 | 2023-01-14 | 一株具有抗炎特性的耐久肠球菌菌株、培养方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310060366.7A CN116200305A (zh) | 2023-01-14 | 2023-01-14 | 一株具有抗炎特性的耐久肠球菌菌株、培养方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116200305A true CN116200305A (zh) | 2023-06-02 |
Family
ID=86507085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310060366.7A Pending CN116200305A (zh) | 2023-01-14 | 2023-01-14 | 一株具有抗炎特性的耐久肠球菌菌株、培养方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116200305A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116790402A (zh) * | 2023-01-14 | 2023-09-22 | 西北农林科技大学 | 一株具有抗炎特性的单形拟杆菌菌株、培养方法及应用 |
CN117511773A (zh) * | 2023-10-13 | 2024-02-06 | 健合香港有限公司 | 一株粪肠球菌、复合菌剂及其应用 |
-
2023
- 2023-01-14 CN CN202310060366.7A patent/CN116200305A/zh active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116790402A (zh) * | 2023-01-14 | 2023-09-22 | 西北农林科技大学 | 一株具有抗炎特性的单形拟杆菌菌株、培养方法及应用 |
CN116790402B (zh) * | 2023-01-14 | 2024-05-14 | 西北农林科技大学 | 一株具有抗炎特性的单形拟杆菌菌株、培养方法及应用 |
CN117511773A (zh) * | 2023-10-13 | 2024-02-06 | 健合香港有限公司 | 一株粪肠球菌、复合菌剂及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gharib et al. | Comparison of the effects of probiotic, organic acid and medicinal plant on Campylobacter jejuni challenged broiler chickens | |
JP5186077B2 (ja) | ラクトバシラス−カゼイke01株から得られたプロバイオティック化合物 | |
Wu et al. | Effects of the antimicrobial peptide cecropin AD on performance and intestinal health in weaned piglets challenged with Escherichia coli | |
Cao et al. | Effects of a probiotic, Enterococcus faecium, on growth performance, intestinal morphology, immune response, and cecal microflora in broiler chickens challenged with Escherichia coli K88 | |
CN102747003B (zh) | 一株益生屎肠球菌的筛选及应用 | |
CN112011481B (zh) | 一株防治畜禽细菌性腹泻的罗伊氏乳杆菌及其应用 | |
CN110878267A (zh) | 一株唾液乳杆菌及其用途 | |
CN116200305A (zh) | 一株具有抗炎特性的耐久肠球菌菌株、培养方法及应用 | |
CN114806978B (zh) | 约氏乳杆菌sxdt-23及其应用 | |
CN115094012B (zh) | 凝结芽孢杆菌bc-hyc株菌剂的制备方法及应用 | |
CN115820499B (zh) | 一株猪源丁酸梭菌及其在调控肠道健康中的应用 | |
CN109486732B (zh) | 一种长双歧杆菌及其应用 | |
CN115287224A (zh) | 一株改善本源动物肠道微生物发育的牦牛源罗伊氏乳杆菌及其应用 | |
CN113088468B (zh) | 干酪乳杆菌Ma.GLRGJ 1及其应用 | |
CA2100774C (en) | Feed additive and method | |
CN114085789A (zh) | 戊糖片球菌ma.wtpqj01及其应用 | |
CN109652334A (zh) | 一种微生物复合菌剂及其制备方法和应用 | |
Satık | Effects of kefir as a probiotic source on the performance and health of young dairy calves | |
CN117448213A (zh) | 一种抑制产气荚膜梭菌的植物乳杆菌及其后生元和应用 | |
CA2520178A1 (en) | Probiotic compounds derived from lactobacillus casei strain ke01 | |
CN110144307B (zh) | 一种抗肠出血性大肠杆菌的格氏乳杆菌及制备的禽用复合益生菌制剂及应用 | |
CN115216434B (zh) | 一株唾液乳杆菌菌株及其用途 | |
CN114908009B (zh) | 一株口粘液乳杆菌pr63及其应用 | |
CN115651860A (zh) | 凝结芽孢杆菌bc-hyc株及其应用 | |
CN114032200A (zh) | 一种养殖动物的枯草芽孢杆菌饲料添加剂的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |